GreenRoc Accelerates their World Class Project to Production as Early as 2028. Watch the full video here.
London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves as "we", "us", "our". The user of the website is referred to as "you" and "your".
By posting on our share chat boards you are agreeing to the following:
The IP address of all posts is recorded to aid in enforcing these conditions. As a user you agree to any information you have entered being stored in a database. You agree that we have the right to remove, edit, move or close any topic or board at any time should we see fit. You agree that we have the right to remove any post without notice. You agree that we have the right to suspend your account without notice.
Please note some users may not behave properly and may post content that is misleading, untrue or offensive.
It is not possible for us to fully monitor all content all of the time but where we have actually received notice of any content that is potentially misleading, untrue, offensive, unlawful, infringes third party rights or is potentially in breach of these terms and conditions, then we will review such content, decide whether to remove it from this website and act accordingly.
Premium Members are members that have a premium subscription with London South East. You can subscribe here.
London South East does not endorse such members, and posts should not be construed as advice and represent the opinions of the authors, not those of London South East Ltd, or its affiliates.
So if Stalicla are designing a phase 2 trial, they will not start it until they are granted IND status by the FDA? IND status and the already successful coated tablet trial could bring EVG $5.5m in milestone payments earlier than expected in 2024?
CJ, might go up, might go down. But just as you got it wrong on the cash-run: £3.7 million, sufficient to the end if 2024 the CFO says, you seem to have forgotten to listen properly to the interview 😆 They're publishing the trial data from this year's results. And Staclia are already designing the phase 2 trial for autism using EVG products. Neurodisorders are very hot for bio meds atm.
And the general rule is to buy low sell high isn't it?
Usually this half year report doesn’t come until the first week in December, didn’t expect it to come this early.
I thought the report was encouraging as one of the biggest fears for some shareholders is a share placing next year if funds start running out. But the cash reserves are better than I expected. I expected about £3m left in cash by end of September. It looks hopeful that a share placing can be averted next year but it really would be helpful to the share price if EVG would bring clarity on when the payments are likely to be received.
I’m still not buying back in though. There may not be a lot of news coming in for the rest of the year now, the share price soon starts to fall again when no news for weeks on end.
I think the interview is positive for shareholders. Interested in what the new CFO is alluding to with reference to 'plans to increase shareholders value'. He says we'll find out so that's encouraging. Big news is Staclia finishing design of phase 2 autism trial. Hope they hurry up😄
I think you may have sold out a day too early Alf. The cash reserves are better than I expected but there is still a lack of clarity on when Stalicla payments are due.
Unfortunately everything takes forever here and although there is promising work being done how long before any more income streams arrive?
Something will have to go disastrously wrong for Evgen not to receive the $5m from stalicla associated with the IND.
IMO stalicla will already be in discussions with the FDA now that they have the data from Evgen.
Still looking at 2nd 1/4 of 2024 for the next placement. As CJ39 has already alluded to, if the share price doesn't improve the dilution at these levels would be disastrous for existing shareholder value.
Meh! Cash runway appears ok into 2024.
Not entirely sure what the MM are up to today, all the trades apart from the 30,000 this morning were sells, and some are completely out of the market ie around 1.8p. Market price just hasn't been that low
Please tell me that you meant squib Alf.
Well the bounce I was expecting was a bit of a damp squid so I've taken my meager profit and will buy myself a Euro millions ticket for Friday, I'm sure I'll have more luck.
P.s the 20,000 buy at 1.9501 was actually a sell.
I've always described Evgen as a never ending series that is well beyond its sell by date. At the end of each season they leave it with a cliff hanger to entice you back in but the result is always the same.
Positive news & another tick in the box
I wonder if this has enough momentum behind it to close the 3.02p gap.
Was the latest RNS the reason why the bods were advised not to buy, I can't see anything in it to suggest so. They'll definitely be challenged on the next AGM, I wonder what excuse they'll come up with then.
“Previous preclinical studies with SFX-01 on Glioblastoma have been striking”
Any positive signals from the grand funded study then big pharma should jump in to accelerate this research into this devastating disease
Nearly 4 weeks to RNS the start of a study.
Think that says it all really.
Its not exactly dynamic leadership is it.
Finally some news after two months but it’s the same old same old, the start of new studies, it will take god knows how long and brings no cash into the business. EVG needs cash and quickly.
Interesting news but will the drug have a statistically meaningful impact?
Progress of the wait and see variety.
£400
But I bet the majority on here had wished they'd only staked £40
Fair comment
But it's absolutely ginormous compared to your £400 punt Kingalf
Seems to be some buying going on, looks big in share volume but the actual cash equivalent isn't.
Have the bods finally got round to buying, I won't hold my breath.
Was interested why the recent board changes were both noted as interim. The new cfo left his previous company.
why interim